Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.

Mark D GonzalezMeghan A WallaceTiffany HinkErik R DubberkeCarey-Ann D Burnham

Published in: Antimicrobial agents and chemotherapy (2015)

Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.

Keyphrases

clostridium difficile
urinary tract infection
gram negative
microbial community
wastewater treatment
risk assessment
heavy metals
genetic diversity
drug administration